RVL Pharmaceuticals PLC
NASDAQ:RVLP
Intrinsic Value
RVL Pharmaceuticals Plc engages in the development and commercialization of products for neurology and women's health. [ Read More ]
The intrinsic value of one
RVLP
stock under the Base Case scenario is
0.8688
USD.
Compared to the current market price of 0.0024 USD,
RVL Pharmaceuticals PLC
is
Undervalued by 100%.
RVL Pharmaceuticals PLC's market capitalization is 238.5k USD.
RVLP stock price is 0.0024 USD.
RVLP stock price (0.0024 USD) is 100% less than its Intrinsic Value (0.8688 USD).
RVLP stock price (0.0024 USD) is 100% less than its Relative Value (0.8597 USD). Open Relative Valuation
RVLP.
RVLP's Revenue has grown by 6% over the past 12 months.
RVLP's long-term assets (85m USD) exceed its long-term liabilties (69m USD).
RVLP has negative Operating Income for the last twelve months.
RVLP has negative Net Income for the last twelve months.
RVLP's ROE (Return on Equity) for the past 12 months is negative and is equal to -182%.
RVLP's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -55%.
RVLP has positive Gross Profit for the last twelve months.
RVLP's short-term liabilties (68m USD) exceed its short-term assets (26m USD).
RVLP has negative Free Cash Flow for the last twelve months.
RVLP's D/E (Debt to Equity) is very low and is equal to 0.
RVLP has negative three-year average ROE (Return on Equity): -108%. The company is not efficient at transforming stockholders' equity into net income.
RVLP has negative three-year average ROIC (Return on Invested Capital): -49%. The company is not efficient at using invested capital to generate operating income.
RVLP has negative Net Debt. This means that the company has more cash and short-term investments (19m USD) than debt (12k USD).
RVLP's Altman Z-Score is very low and is equal to -11.51.
RVLP doesn't generate enough operating income (-43m USD) to safely cover interest payments on its debt (9m USD).
Fundamental Analysis
RVL Pharmaceuticals PLC
Balance Sheet Decomposition
RVL Pharmaceuticals PLC
| Current Assets | 25.8m |
| Cash & Short-Term Investments | 19.2m |
| Receivables | 1.9m |
| Other Current Assets | 4.7m |
| Non-Current Assets | 59.7m |
| PP&E | 3.8m |
| Intangibles | 55.8m |
| Current Liabilities | 68.4m |
| Accounts Payable | 2.5m |
| Accrued Liabilities | 7m |
| Other Current Liabilities | 58.9m |
| Non-Current Liabilities | 686k |
| Long-Term Debt | 12k |
| Other Non-Current Liabilities | 674k |
Earnings Waterfall
RVL Pharmaceuticals PLC
|
Revenue
|
36.9m
USD
|
|
Cost of Revenue
|
-9.3m
USD
|
|
Gross Profit
|
27.6m
USD
|
|
Operating Expenses
|
-70.2m
USD
|
|
Operating Income
|
-42.6m
USD
|
|
Other Expenses
|
-25.7m
USD
|
|
Net Income
|
-68.3m
USD
|
Free Cash Flow Analysis
RVL Pharmaceuticals PLC
RVLP Profitability Score
Profitability Due Diligence
RVL Pharmaceuticals PLC's profitability score is 24/100. The higher the profitability score, the more profitable the company is.
Score
RVL Pharmaceuticals PLC's profitability score is 24/100. The higher the profitability score, the more profitable the company is.
RVLP Solvency Score
Solvency Due Diligence
RVL Pharmaceuticals PLC's solvency score is 38/100. The higher the solvency score, the more solvent the company is.
Score
RVL Pharmaceuticals PLC's solvency score is 38/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
RVLP Price Targets Summary
RVL Pharmaceuticals PLC
Ownership
RVLP Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
RVLP Price
RVL Pharmaceuticals PLC
| Average Annual Return | -15.91% |
| Standard Deviation of Annual Returns | 71.5% |
| Max Drawdown | -100% |
| Market Capitalization | 238.5k USD |
| Shares Outstanding | 99 349 800 |
| Percentage of Shares Shorted | 4.54% |
Company Profile
RVL Pharmaceuticals PLC
Country
Industry
Market Cap
Dividend Yield
Description
RVL Pharmaceuticals Plc engages in the development and commercialization of products for neurology and women's health. The company is headquartered in Bridgewater, New Jersey and currently employs 156 full-time employees. The company went IPO on 2018-10-12. The firm is focused on developing and commercializing eyecare and medical aesthetics products. The firm is engaged in the development of products that target markets with underserved patient populations in the ocular and medical aesthetics therapeutic areas. The firm delivers Upneeq (oxymetazoline hydrocholoride ophthalmic solution, 0.1%) for the treatment of acquired blepharoptosis, or low-lying eyelids, in adults. Upneeq is the non-surgical treatment option for acquired blepharoptosis.
You don't have any saved screeners yet
